Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).Narcolepsy type 2, also known as narcolepsy without cataplexy, is a sleep disorder characterized by excessive daytime sleepiness (EDS). Unlike type 1, it typically does not include cataplexy (sudden muscle weakness triggered by emotions).In the trial, once-daily alixorexton met the dual primary endpoints, demonstrating statisti ...